PL2054040T3 - Sposób wytwarzania stałych dyspersji midostauryny - Google Patents

Sposób wytwarzania stałych dyspersji midostauryny

Info

Publication number
PL2054040T3
PL2054040T3 PL07811314T PL07811314T PL2054040T3 PL 2054040 T3 PL2054040 T3 PL 2054040T3 PL 07811314 T PL07811314 T PL 07811314T PL 07811314 T PL07811314 T PL 07811314T PL 2054040 T3 PL2054040 T3 PL 2054040T3
Authority
PL
Poland
Prior art keywords
solid dispersions
midostaurin
making solid
highly crystalline
compounds
Prior art date
Application number
PL07811314T
Other languages
English (en)
Inventor
Indrajit Ghosh
Jennifer Snyder
Wei-Qin Tong
Sudha Vippagunta
Original Assignee
Novartis Ag
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Novartis Ag filed Critical Novartis Ag
Publication of PL2054040T3 publication Critical patent/PL2054040T3/pl

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A61K9/1605—Excipients; Inactive ingredients
    • A61K9/1629—Organic macromolecular compounds
    • A61K9/1641—Organic macromolecular compounds obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyethylene glycol, poloxamers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
    • A61K47/34—Macromolecular compounds obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyesters, polyamino acids, polysiloxanes, polyphosphazines, copolymers of polyalkylene glycol or poloxamers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Epidemiology (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Inorganic Chemistry (AREA)
  • Medicinal Preparation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Colloid Chemistry (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
  • Compositions Of Macromolecular Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Glass Compositions (AREA)
  • Peptides Or Proteins (AREA)
PL07811314T 2006-08-16 2007-08-14 Sposób wytwarzania stałych dyspersji midostauryny PL2054040T3 (pl)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US82255606P 2006-08-16 2006-08-16
EP07811314A EP2054040B1 (en) 2006-08-16 2007-08-14 Method for making solid dispersions of midostaurin
PCT/US2007/017960 WO2008021347A2 (en) 2006-08-16 2007-08-14 Method for making solid dispersions of highly crystalline therapeutic compounds

Publications (1)

Publication Number Publication Date
PL2054040T3 true PL2054040T3 (pl) 2011-09-30

Family

ID=38657762

Family Applications (1)

Application Number Title Priority Date Filing Date
PL07811314T PL2054040T3 (pl) 2006-08-16 2007-08-14 Sposób wytwarzania stałych dyspersji midostauryny

Country Status (16)

Country Link
US (2) US20100038816A1 (pl)
EP (1) EP2054040B1 (pl)
JP (1) JP5546860B2 (pl)
KR (1) KR101462693B1 (pl)
CN (1) CN101516339B (pl)
AT (1) ATE503484T1 (pl)
AU (1) AU2007284615B2 (pl)
BR (1) BRPI0714963A2 (pl)
CA (1) CA2660086C (pl)
DE (1) DE602007013567D1 (pl)
ES (1) ES2363725T3 (pl)
MX (1) MX2009001636A (pl)
PL (1) PL2054040T3 (pl)
PT (1) PT2054040E (pl)
RU (1) RU2454220C2 (pl)
WO (1) WO2008021347A2 (pl)

Families Citing this family (26)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP1923053A1 (en) 2006-09-27 2008-05-21 Novartis AG Pharmaceutical compositions comprising nilotinib or its salt
WO2009100176A2 (en) * 2008-02-07 2009-08-13 Abbott Laboratories Pharmaceutical dosage form for oral administration of tyrosine kinase inhibitor
KR20110003383A (ko) * 2008-04-30 2011-01-11 노파르티스 아게 제약 조성물의 연속 제조 방법
EP2327706A1 (en) * 2009-11-30 2011-06-01 Novartis AG Polymorphous forms III and IV of N-benzoyl-staurosporine
UA113500C2 (xx) 2010-10-29 2017-02-10 Одержані екструзією розплаву тверді дисперсії, що містять індукуючий апоптоз засіб
CN102525879B (zh) * 2010-12-31 2015-01-21 正大天晴药业集团股份有限公司 制备阿瑞匹坦固体分散组合物的方法
CN111808276A (zh) 2014-03-25 2020-10-23 豪夫迈·罗氏有限公司 制备用于细胞培养基中的泊洛沙姆的方法
KR20170095972A (ko) 2014-12-18 2017-08-23 머크 샤프 앤드 돔 코포레이션 제약 제제용 (s)-n-(3-(6-이소프로폭시피리딘-3-일)-1h-인다졸-5-일)-1-(2-(4-(4-(1-메틸-1h-1,2,4-트리아졸-3-일)페닐)-3,6-디히드로피리딘-1(2h)-일)-2-옥소에틸)-3-(메틸티오)피롤리딘-3-카르복사미드 조성물
GB201502073D0 (en) * 2015-02-09 2015-03-25 Cubic Pharmaceuticals Ltd And Delta Pharmaceuticals Ltd HDEG technology
EP3337454B1 (en) 2015-08-20 2018-12-26 Unilever Plc. Improved lactam solubility
CN107848968B (zh) 2015-08-20 2021-06-18 荷兰联合利华有限公司 从乙醛酸制备内酰胺的方法
EP3337451B1 (en) 2015-08-20 2018-12-26 Unilever PLC Improved lactam solubility
CN108024939B (zh) 2015-08-20 2024-06-07 联合利华知识产权控股有限公司 包封的内酰胺
BR112018003182B1 (pt) 2015-08-20 2021-07-13 Unilever Ip Holdings B.V. Composição que compreende lactama e tensoativo não iônico
BR112018003082B1 (pt) * 2015-08-20 2021-12-14 Unilever Ip Holdings B.V. Lactama em uma dispersão sólida, método de produção de uma composição compreendendo uma lactama e método de formação de lactama em uma dispersão sólida
WO2017029092A1 (en) 2015-08-20 2017-02-23 Unilever Plc Improved lactam solubility
WO2017163072A1 (en) * 2016-03-24 2017-09-28 Locate Therapeutics Limited Scaffolding material, methods and uses
JP6955517B2 (ja) * 2016-05-13 2021-10-27 メルク パテント ゲゼルシャフト ミット ベシュレンクテル ハフツングＭｅｒｃｋ Ｐａｔｅｎｔ Ｇｅｓｅｌｌｓｃｈａｆｔ ｍｉｔ ｂｅｓｃｈｒａｅｎｋｔｅｒ Ｈａｆｔｕｎｇ 可塑剤として直接圧縮可能な賦形剤を使用する加熱溶融押出組成物
EP3520782A3 (en) * 2018-02-01 2019-11-13 Corvus Pharmaceuticals, Inc. Pharmaceutical formulations containing adenosine a2a receptor antagonists
CA3084182A1 (en) 2018-02-01 2019-08-08 Corvus Pharmaceuticals, Inc. Pharmaceutical formulations
JP7211644B2 (ja) 2019-02-18 2023-01-24 スレイバック・ファーマ・エルエルシー ニロチニブの医薬組成物
AU2021391823A1 (en) 2020-12-03 2023-06-29 Battelle Memorial Institute Polymer nanoparticle and dna nanostructure compositions and methods for non-viral delivery
US12031128B2 (en) 2021-04-07 2024-07-09 Battelle Memorial Institute Rapid design, build, test, and learn technologies for identifying and using non-viral carriers
CN114796149A (zh) * 2022-04-27 2022-07-29 苏州中化药品工业有限公司 一种高生物利用度的双醋瑞因胶囊剂及其制备方法
WO2025072751A1 (en) 2023-09-29 2025-04-03 Battelle Memorial Institute Polymer nanoparticle compositions for in vivo expression of polypeptides
WO2025122954A1 (en) 2023-12-08 2025-06-12 Battelle Memorial Institute Use of dna origami nanostructures for molecular information based data storage systems

Family Cites Families (39)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE3346123A1 (de) 1983-12-21 1985-06-27 Janssen Pharmaceutica, N.V., Beerse Pharmazeutische praeparate von in wasser schwerloeslichen oder instabilen arzneistoffen und verfahren zu ihrer herstellung
IE80467B1 (en) 1995-07-03 1998-07-29 Elan Corp Plc Controlled release formulations for poorly soluble drugs
US5837714A (en) * 1997-03-03 1998-11-17 Sanofi Solid pharmaceutical dispersions
ATE232087T1 (de) 1997-10-27 2003-02-15 Merck Patent Gmbh Feste lösungen und dispersionen von eines schlecht wasserlöslichen wirkstoffes
US6706283B1 (en) * 1999-02-10 2004-03-16 Pfizer Inc Controlled release by extrusion of solid amorphous dispersions of drugs
GB9903547D0 (en) * 1999-02-16 1999-04-07 Novartis Ag Organic compounds
US20060034937A1 (en) * 1999-11-23 2006-02-16 Mahesh Patel Solid carriers for improved delivery of active ingredients in pharmaceutical compositions
US6593308B2 (en) * 1999-12-03 2003-07-15 The Regents Of The University Of California Targeted drug delivery with a hyaluronan ligand
US20020015730A1 (en) * 2000-03-09 2002-02-07 Torsten Hoffmann Pharmaceutical formulations and method for making
DE10013289A1 (de) * 2000-03-17 2001-09-20 Knoll Ag Torasemid enthaltende pharmazeutische Zubereitungen
ATE326216T1 (de) * 2001-03-26 2006-06-15 Novartis Pharma Gmbh Pharmazeutische zusammensetzung enthaltend ein schlecht wasserlösliches staurosporin, eine oberflächenaktive substanz und ein wasserlösliches polymer
CN1255185C (zh) * 2001-05-03 2006-05-10 弗·哈夫曼-拉罗切有限公司 无定形甲磺酸奈非那韦的药物剂型
US20030212102A1 (en) * 2001-06-12 2003-11-13 Koretke Todd W Novel solid dispersion compositions
JP4644397B2 (ja) * 2001-09-05 2011-03-02 信越化学工業株式会社 難溶性薬物を含む医薬用固形製剤の製造方法
US7049322B2 (en) * 2002-02-21 2006-05-23 Supergen, Inc. Compositions and formulations of 9-nitrocamptothecin polymorphs and methods of use therefor
GB0205253D0 (en) * 2002-03-06 2002-04-17 Univ Gent Immediate release pharmaceutical granule compositions and a continuous process for making them
US8268352B2 (en) * 2002-08-05 2012-09-18 Torrent Pharmaceuticals Limited Modified release composition for highly soluble drugs
US7230012B2 (en) * 2002-11-14 2007-06-12 Celgene Corporation Pharmaceutical compositions and dosage forms of thalidomide
GB0315012D0 (en) * 2003-06-27 2003-07-30 Leuven K U Res & Dev Zeotiles
US20050080075A1 (en) * 2003-08-25 2005-04-14 Nichols M. James Formulations, conjugates, and combinations of drugs for the treatment of neoplasms
US20050208095A1 (en) * 2003-11-20 2005-09-22 Angiotech International Ag Polymer compositions and methods for their use
KR20060101762A (ko) * 2003-11-21 2006-09-26 쉐링 코포레이션 포스포디에스테라제 ｖ 억제제 제형
WO2005053727A2 (en) * 2003-11-29 2005-06-16 Sangstat Medical Corporation Pharmaceutical compositions for bioactive peptide agents
EA013427B1 (ru) * 2004-03-15 2010-04-30 Такеда Фармасьютикал Компани Лимитед Ингибиторы дипептидилпептидазы
US20060246109A1 (en) * 2005-04-29 2006-11-02 Hossainy Syed F Concentration gradient profiles for control of agent release rates from polymer matrices
US20050288481A1 (en) * 2004-04-30 2005-12-29 Desnoyer Jessica R Design of poly(ester amides) for the control of agent-release from polymeric compositions
US20090075972A1 (en) * 2004-08-31 2009-03-19 Jan Cools Use of Midostaurin for Treating Gastrointestinal Stromal Tumors
US20080038316A1 (en) * 2004-10-01 2008-02-14 Wong Vernon G Conveniently implantable sustained release drug compositions
JO2897B1 (en) * 2004-11-05 2015-09-15 نوفارتيس ايه جي Organic compounds
US20090088465A1 (en) * 2004-12-02 2009-04-02 Stephen Craig Dyar Pharmaceutical Compositions of Amorphous Atorvastatin and Process for Preparing Same
WO2007068615A2 (en) * 2005-12-14 2007-06-21 F. Hoffmann-La Roche Ag Hcv prodrug formulation
PT2530083T (pt) * 2006-09-22 2016-08-01 Pharmacyclics Llc Inibidores de tirosina cinase de bruton
US8258137B2 (en) * 2008-01-29 2012-09-04 Katholieke Universiteit Leuven Process for release of biologically active species from mesoporous oxide systems
CN102413839A (zh) * 2009-03-06 2012-04-11 医学免疫有限责任公司 人源化抗cd19抗体制剂
TW201120037A (en) * 2009-10-26 2011-06-16 Sunesis Pharmaceuticals Inc Compounds and methods for treatment of cancer
EP2327706A1 (en) * 2009-11-30 2011-06-01 Novartis AG Polymorphous forms III and IV of N-benzoyl-staurosporine
MX342405B (es) * 2010-06-03 2016-09-28 Pharmacyclics Inc El uso de inhibidores de la tirosina quinasa de bruton (btk).
CA2811601A1 (en) * 2010-09-24 2012-03-29 Mallinckrodt Llc Aptamer conjugates for targeting of therapeutic and/or diagnostic nanocarriers
CA2828483A1 (en) * 2011-02-23 2012-11-01 Intellikine, Llc Combination of kinase inhibitors and uses thereof

Also Published As

Publication number Publication date
CN101516339A (zh) 2009-08-26
DE602007013567D1 (de) 2011-05-12
US20100038816A1 (en) 2010-02-18
JP5546860B2 (ja) 2014-07-09
MX2009001636A (es) 2009-02-23
EP2054040A2 (en) 2009-05-06
CA2660086A1 (en) 2008-02-21
EP2054040B1 (en) 2011-03-30
ATE503484T1 (de) 2011-04-15
JP2010500411A (ja) 2010-01-07
WO2008021347A3 (en) 2008-08-07
AU2007284615B2 (en) 2011-10-27
BRPI0714963A2 (pt) 2013-07-30
CA2660086C (en) 2014-09-16
KR20090042961A (ko) 2009-05-04
US20120190667A1 (en) 2012-07-26
WO2008021347A2 (en) 2008-02-21
US8641948B2 (en) 2014-02-04
PT2054040E (pt) 2011-06-30
RU2454220C2 (ru) 2012-06-27
KR101462693B1 (ko) 2014-11-17
RU2009109357A (ru) 2010-09-27
ES2363725T3 (es) 2011-08-12
CN101516339B (zh) 2012-06-13
AU2007284615A1 (en) 2008-02-21

Similar Documents

Publication Publication Date Title
PL2054040T3 (pl) Sposób wytwarzania stałych dyspersji midostauryny
IL189686A0 (en) Optically active diamine derivative and process for producing the same
TWI371461B (en) Polyvinyl alcohol film, and process for producing the same
IL221579A (en) Foams, pre-blended compositions, and inflating materials containing fluorinated olefins and foam preparation methods
NZ592897A (en) Crystals of laquinimod sodium, and process for the manufacture thereof
ZA200810228B (en) Thermoplastic articles and processes for making the same using an improved masterbatch
EP1873847A4 (en) CATHODE ACTIVE MATERIAL AND METHOD OF MANUFACTURING THE SAME
NL2000375A1 (nl) Pyrimidinederivaten voor de behandeling van abnormale celgroei.
EP2028222A4 (en) ORIENTED POLYMER FILM OF NORBORNENE COMPOUND ADDITION ONLY, PROCESS FOR PRODUCTION THEREOF, AND USE THEREOF
EP2062601A4 (en) FOAM AND PROCESS FOR PRODUCING THE SAME
ZA200706113B (en) Method for the treatment of copper-bearing materials
EP1911538A4 (en) EDGE REPLACEMENT CUTTING HEAD AND METHOD FOR PRODUCING THE SAME
MX2009004030A (es) Articulos antimicrobianos y metodos de fabricacion.
SG136072A1 (en) Tetrahydronaphthalene derivatives, processes for preparing them and their use as antiinflammatory agents
PT1748990E (pt) Processo para a preparação de telmisartan
GB2433835B (en) Organic thin film transistor and method for manufacturing the same
EP1916241A4 (en) CRYSTAL OF A PHENYLALANINE DERIVATIVE, METHOD FOR THE PRODUCTION THEREOF AND ITS USE
SI1926476T1 (sl) Amorfne trdne disperzije 7-kloro-N,N,5-trimetil-4-okso-3-fenil-3,5- dihidro-4H-piridazino/4,5-b/indol-1-acetamida
PL1873158T3 (pl) Kryształy pochodnej morfinanu i sposoby ich wytwarzania
GB0915454D0 (en) Novel benzothiazole and benzoxazole linked pyrrolo (2,1-C) (1,4) benzodiazepine hybrids as novel antitumour agents and process for the preparation thereof
EP1935883A4 (en) OXINDOL DERIVATIVES AS A MEANS FOR CONTROLLING FOOD RECEPTION
AU2008306604A8 (en) Process for the preparation of zolmitriptan, salts and solvates thereof
EP1833955B8 (en) Plasticized article for treating the skin
EP1951454A4 (en) METHOD FOR THE TEMPERATURE TREATMENT OF EXTRUSION TOOLS
ZA200903936B (en) Method for the production of an agent against an infectuous disease